ReviewDrugs2019
Teriflunomide: A Review in Relapsing-Remitting Multiple Sclerosis.
Review in Drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 39 citations in OpenAlex.
- Therapeutic Approaches for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis: Current and Emerging Strategies.Pathogens (Basel, Switzerland) · 2026Review
- Integrative biochemical and computational analysis of leflunomide-induced redox alterations in Nauphoeta cinerea.Scientific reports · 2025Article
- The Variant rs7665090 Is Associated With Interferon-Beta Response in Multiple Sclerosis Patients.European journal of neurology · 2025Article
- Article
- Expanding Field of Dermatological Side Effects of Pharmaceuticals.Acta dermato-venereologica · 2024Article
- Implications of immunometabolism for smouldering MS pathology and therapy.Nature reviews. Neurology · 2023Review
- Focal segmental glomerulosclerosis in a patient with multiple sclerosis treated with Teriflunomide and Ocrelizumab.Journal of nephrology · 2023Article
- In-depth characterization of long-term humoral and cellular immune responses to COVID-19m-RNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumab.Multiple sclerosis and related disorders · 2023Article
- Synergistic potential of teriflunomide with fluconazole against resistantFrontiers in cellular and infection microbiology · 2023Article
- Real-world outcomes of teriflunomide in relapsing-remitting multiple sclerosis: a prospective cohort study.Journal of neurology · 2022Observational
- Adverse Drug Reactions with Drugs Used in Multiple Sclerosis: An Analysis from the Italian Pharmacovigilance Database.Frontiers in pharmacology · 2022Article
- Teriflunomide provides protective properties after oxygen-glucose-deprivation in hippocampal and cerebellar slice cultures.Neural regeneration research · 2021Article
- Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study.Journal of neurology · 2021Article
- Leflunomide Loaded Chitosan Nanoparticles for the Preparation of Aliphatic Polyester Based Skin Patches.Polymers · 2021Article
- Article
- Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide.Journal of the neurological sciences · 2020Article
- Teriflunomide treatment outcomes in multiple sclerosis: A Portuguese real-life experience.Brain and neuroscience advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Teriflunomide (Aubagio
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.